UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: July 2020 (Report No. 3)

 

Commission file number: 001-38041

 

THERAPIX BIOSCIENCES LTD.

(Translation of registrant’s name into English)

 

4 Ariel Sharon Street

HaShahar Tower, 16th Floor

Givatayim 5320047, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____ 

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is a press release issued by Therapix Biosciences Ltd. (the “Registrant”) on July 9, 2020, titled “Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court.”

 

The press release is incorporated by reference into the registration statements on Form F-3 (File No. 333-225745 and File No. 333-233417) and on Form S-8 (File No. 333-225773) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit No.    
99.1   Press Release issued by Therapix Biosciences Ltd. on July 9, 2020, titled “Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court.”

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Therapix Biosciences Ltd.
Date: July 9, 2020  
  By:  /s/ Oz Adler
    Name: Oz Adler
Title:   Chief Financial Officer

 

2

Exhibit 99.1

 


Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court

TEL AVIV, Israel, July 9, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that its American Depositary Shares ("ADSs") will now trade under the OTC Pink ticker symbol "TRPXY." The Company also announced the removal by an Israeli court of a previously reported temporary injunction against the Company prohibiting the Company from making any changes in its share capital or adopting any resolution which is not in the ordinary course of business. 

THERAPIX BIOSCIENCES LOGO

 OTC Pink Ticker Symbol "TRPXY"

As of July 8, 2020, the Company's ADSs became eligible to trade on the OTC Pink Marketplace under the symbols "TRPXY."  The Company previously announced that the listing of its ADSs was suspended by the Nasdaq Stock Market as of July 2, 2020.  The Company can provide no assurance that its securities will commence or continue to trade on the OTC Pink marketplace, whether broker-dealers will continue to provide public quotes of the Company's securities on this market or whether the trading volume of the Company's securities will be sufficient to provide for an efficient trading market.

Injunction Removal from Israeli Court

On July 8, 2020, during a court hearing following the previously granted temporary injunction, the Israeli court ruled as follows:

1.  The parties have reached a mutual agreement that L.I.A. Pure Capital shall cancel the application for the temporary injunction, subject to the Company's commitment that (i) the previously announced Annual and Special General Meeting of Shareholders (the "Meeting") will be held on July 28, 2020 as planned, and (ii) the record date for the Meeting will be July 7, 2020.

2.  In the event the Meeting is convened and a quorum is not present, the Meeting will be held one week later, on August 4, 2020.

3.  The Company confirmed that its previously announced private placement of ADSs was terminated and is no longer in effect, and the ADSs that were to be issued under such private placement shall therefore not be entitled to vote in the Meeting since they were not issued.

About Therapix Biosciences (OTC Pink: TRPXY):

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Please visit our website for more information at www.therapixbio.com, the content of which is not a part of this press release.

Logo - http://mma.prnewswire.com/media/507393/Therapix_Biosciences_Logo.jpg

Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com